Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01061671 · ClinicalTrials.gov registry record · Phase 3
Simvastatin Therapy for Moderate and Severe COPD
A Phase 3 study, sponsored by University of Minnesota.
- Terminated
- Registry status
- Phase 3
- Development phase
- 885
- Enrollment target
NCT01061671 is a Phase 3 study that was terminated before completion, run by University of Minnesota. The registered enrollment target is 885 participants.
The verdict
NCT01061671, a Phase 3 study, was terminated before completion, sponsored by University of Minnesota.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 885 participants
- Enrollment target
Study Summary
To determine the effect of daily administration of 40 mgms simvastatin taken for at least 12 months (range 12-36 months) on the frequency of exacerbations of chronic obstructive lung disease (COPD) in patients with moderate to severe COPD who are prone to exacerbations and do not have other indications for statin treatment.
Interventions
- DRUG Placebo
- DRUG simvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 885 participants |
| Start Date | 2010-03 |
| Est. Completion | 2014-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01061671
The ClinicalTrials.gov registry entry for NCT01061671 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 885 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01061671 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01061671 about?
NCT01061671 is a clinical study titled "Simvastatin Therapy for Moderate and Severe COPD". To determine the effect of daily administration of 40 mgms simvastatin taken for at least 12 months (range 12-36 months) on the frequency of exacerbations of chronic obstructive lung disease (COPD) in patients with moderate to severe COPD who are prone to exacerbations and do not have other indicati...
What is the current status of trial NCT01061671?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 885 participants. The study started on 2010-03. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01061671?
The interventions under investigation include: Placebo (DRUG), simvastatin (DRUG).
Who is sponsoring clinical trial NCT01061671?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.